Volume 13, Number 1, January-February 2006

Heart disease prevention – what place for the glitazones?
Michael Kirby

This paper considers the role for glitazones in the treatment of type 2 diabetes following publication of the PROactive study, the first major outcome study with this class of agents. The macrovascular benefits of glitazones are discussed. Recent guidance for glitazone prescribing from the Association of British Clinical Diabetologists is also given.

Br J Cardiol 2006;13:66-70.

View full PDF article (open in new window)
Email this article